March 19, 2014
1 min read
Save

Ocular Therapeutix begins phase 3 trial of sustained-release corticosteroid

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A phase 3 clinical program will investigate the safety and efficacy of sustained-release dexamethasone, a corticosteroid to treat inflammation and pain after cataract surgery, according to a press release from Ocular Therapeutix.

A one-time intracanalicular plug releases the steroid to the ocular surface for up to 30 days.

Two prospective, multicenter, randomized, parallel-arm, doubled-masked, vehicle-controlled studies are planned. In the first study, 240 clear corneal cataract surgery patients in the U.S. will be randomized to either dexamethasone treatment or a placebo plug. The primary endpoints include the absence of anterior chamber cells at day 14 and reduction of pain at day 8, the release said.

The second phase 3 trial will begin later this year.